Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in EUR (TTM)184.98m
- Net income in EUR-461.54m
- Incorporated1998
- Employees446.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 23.13m | -6.16m | 584.86m | 160.00 | -- | 8.90 | -- | 25.29 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Abivax SA | 0.00 | -177.43m | 643.07m | 62.00 | -- | 5.05 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.03m | -687.06k | 652.95m | 156.00 | -- | 33.97 | 539.75 | 4.16 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Kuros Biosciences AG | 55.37m | -9.36m | 798.03m | 80.00 | -- | 12.37 | -- | 14.41 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Formycon AG | 60.80m | 63.90m | 856.36m | 239.00 | 12.13 | 1.49 | 12.98 | 14.08 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Evotec SE | 788.44m | -170.69m | 1.07bn | 5.02k | -- | 1.05 | -- | 1.35 | -0.9634 | -0.9634 | 4.45 | 5.70 | 0.3667 | 18.94 | 4.10 | 155,787.40 | -7.94 | -0.0064 | -9.88 | -0.0076 | 15.98 | 24.51 | -21.65 | -0.0178 | 1.73 | -1.70 | 0.3189 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BioArctic AB | 26.36m | -7.77m | 1.09bn | 96.00 | -- | 16.03 | 263.61 | 41.51 | -0.9972 | -0.9972 | 3.39 | 10.52 | 0.2699 | -- | -- | 3,401,659.00 | -7.96 | 2.24 | -8.90 | 2.56 | 88.22 | 86.52 | -29.49 | 9.76 | -- | -- | 0.0604 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Gubra A/S | 27.49m | -5.97m | 1.11bn | 219.00 | -- | 17.19 | -- | 40.35 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Genus plc | 798.19m | 9.43m | 1.45bn | 3.48k | 155.62 | 2.22 | 24.68 | 1.82 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.37 | -- | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.42 | 279.50 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| AddLife AB | 879.39m | 10.39m | 1.66bn | 2.32k | 165.55 | 3.80 | 18.01 | 1.89 | 0.9683 | 0.9683 | 81.96 | 42.19 | 0.7438 | 3.47 | 5.30 | 4,340,287.00 | 0.8937 | 5.31 | 1.37 | 8.83 | 37.24 | 36.89 | 1.20 | 5.79 | 0.4779 | 1.67 | 0.5113 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Galapagos NV | 304.96m | 31.50m | 1.74bn | 683.00 | 55.15 | 0.5973 | -- | 5.70 | 0.4783 | 4.29 | 4.63 | 44.16 | 0.0692 | 0.442 | 6.01 | 472,080.50 | 0.7149 | -1.48 | 0.7902 | -1.65 | 88.04 | -- | 10.33 | -14.42 | 9.87 | -- | 0.0037 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| BB BIOTECH AG | 285.32m | 246.73m | 2.16bn | -- | 8.71 | 0.8513 | -- | 7.58 | 4.26 | 4.26 | 4.95 | 43.52 | 0.1024 | -- | 117.67 | -- | 8.86 | 2.34 | 10.07 | 2.52 | 97.69 | 99.06 | 86.47 | 35.40 | -- | -- | 0.118 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| MorphoSys AG | 184.98m | -461.54m | 2.55bn | 446.00 | -- | -- | -- | 13.79 | -12.48 | -12.59 | 5.13 | -8.89 | 0.0962 | 0.7357 | 5.08 | 353,012.10 | -23.99 | -10.25 | -31.72 | -11.61 | 85.74 | 85.92 | -249.51 | -78.53 | 0.7747 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
Data as of Sep 23 2024. Currency figures normalised to MorphoSys AG's reporting currency: Euro EUR
25.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 22 Jan 2024 | 1.89m | 5.01% |
| Norges Bank Investment Managementas of 10 May 2024 | 1.69m | 4.48% |
| RP Management LLC (Investment Management)as of 16 Feb 2024 | 1.34m | 3.55% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 May 2024 | 1.08m | 2.88% |
| Caligan Partners LPas of 28 Feb 2023 | 1.06m | 2.81% |
| DWS Investment GmbHas of 02 May 2024 | 868.00k | 2.30% |
| Baillie Gifford & Co.as of 16 Dec 2022 | 835.29k | 2.22% |
| Candriam Belgium SAas of 30 Apr 2024 | 347.52k | 0.92% |
| Union Investment Privatfonds GmbHas of 21 Nov 2023 | 247.04k | 0.66% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 170.34k | 0.45% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
